A single-arm study evaluating the relative dose intensity of IV CMF [cyclophosphamide + methotrexate + fluorouracil] given on day 1 and day 8 with pegfilgrastim support in subjects with stage I-III breast cancer

Trial Profile

A single-arm study evaluating the relative dose intensity of IV CMF [cyclophosphamide + methotrexate + fluorouracil] given on day 1 and day 8 with pegfilgrastim support in subjects with stage I-III breast cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2010

At a glance

  • Drugs Cyclophosphamide; Fluorouracil; Methotrexate
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Feb 2010 Trial location (Spain) added as reported by ClinicalTrials.gov record.
    • 11 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top